We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Transient osteoporosis of the hip following discontinuation of denosumab and switch to alendronate treatment.
- Authors
Makras, Polyzois; Yavropoulou, Maria P.; Anastasilakis, Athanasios D.; Papatheodorou, Athanasios; Tekedis, Christos; Papapoulos, Socrates E.
- Abstract
The article focuses on a case study of a patient who developed transient osteoporosis (TO) of the hip after discontinuing denosumab and switching to alendronate treatment. Topics include the efficacy of bisphosphonates in managing bone marrow edema syndrome/transient osteoporosis, the impact of denosumab discontinuation on bone turnover markers, and concerns regarding the use of alendronate in patients with Bone Marrow Edema Syndrome developed after denosumab discontinuation.
- Subjects
THERAPEUTIC use of monoclonal antibodies; DRUG therapy; DISABILITY evaluation; GAIT in humans; MAGNETIC resonance imaging; FUNCTIONAL status; HIP joint; MONOCLONAL antibodies; INTRAVENOUS therapy; ALENDRONATE; PAIN; ZOLEDRONIC acid; OSTEOPOROSIS
- Publication
Osteoporosis International, 2024, Vol 35, Issue 4, p741
- ISSN
0937-941X
- Publication type
Letter to the Editor
- DOI
10.1007/s00198-023-07000-5